Naga Rajiv Lakkaniga

Indian Institute of Technology (Indian School of Mines)

H指数:17

被引数:863

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

TTK Overexpression as a Prognostic Indicator and Immune Modulator in Kidney Renal Clear Cell Carcinoma

TTK过表达作为肾透明细胞癌的预后指标和免疫调节剂

Molecular Carcinogenesis

IF3.2

2026-05-260

PRE

Synergistic Combinations for Improved Therapeutic Outcomes in Triple Negative Breast Cancer

三阴性乳腺癌中改善治疗效果的协同组合

Cell Biology International

IF3.1

2026-04-160

PRE

Evaluating the FEP+ protocol for predicting binding affinity of congeneric ligands towards various soluble proteins

评估FEP+协议在预测同系配体与各种可溶性蛋白质结合亲和力方面的应用

RSC Med. Chem.

IF3.6

2025-10-310

PRE

Evolution of structure-guided drug design strategies targeting mutations in codon 12 of KRAS

靶向KRAS基因第12密码子突变的结构导向药物设计策略的演变

RSC Med. Chem.

IF3.6

2025-08-140

PRE

Exploring the Conformational Space of MPS1 Kinase Using Metadynamics

PROTEINS-STRUCTURE FUNCTION AND BIOINFORMATICS

IF2.8

2025-01-090

PRE

Comprehensive insights into rheumatoid arthritis: Pathophysiology, current therapies and herbal alternatives for effective disease management

PHYTOTHERAPY RESEARCH

IF6.3

2024-03-245

PRE

Pyrazolopyridine-based kinase inhibitors for anti-cancer targeted therapy

RSC MEDICINAL CHEMISTRY

IF3.6

2024-01-014

PRE

Kinase inhibitor macrocycles: a perspective on limiting conformational flexibility when targeting the kinome with small molecules

RSC MEDICINAL CHEMISTRY

IF3.6

2024-01-017

PRE

Revisiting Aurora Kinase B: A promising therapeutic target for cancer therapy

重温极光激酶B: 癌症治疗的有希望的治疗靶点

MEDICINAL RESEARCH REVIEWS

IF11.6

2023-11-204

An innovative approach for predicting pandemic hotspots in complex wastewater networks using graph theory coupled with fuzzy logic

STOCHASTIC ENVIRONMENTAL RESEARCH AND RISK ASSESSMENT

IF3.6

2023-05-195

OAAI

Discovery of N-Trisubstituted Pyrimidine Derivatives as Type I RET and RET Gatekeeper Mutant Inhibitors with a Novel Kinase Binding Pose

JOURNAL OF MEDICINAL CHEMISTRY

IF6.8

2022-01-279

FLT3 inhibitors for acute myeloid leukemia: successes, defeats, and emerging paradigms

RSC MEDICINAL CHEMISTRY

IF3.6

2022-01-0117

Discovery of imidazo[1,2-a]pyridine-thiophene derivatives as FLT3 and FLT3 mutants inhibitors for acute myeloid leukemia through structure-based optimization of an NEK2 inhibitor

EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY

IF5.9

2021-12-0115

OAAI

Novel hydroxybenzylamine-deoxyvasicinone hybrids as anticholinesterase therapeutics for Alzheimer's disease

BIOORGANIC & MEDICINAL CHEMISTRY

IF3

2021-09-0113

OAAI

Targeting Rearranged during Transfection in Cancer: A Perspective on Small-Molecule Inhibitors and Their Clinical Development

JOURNAL OF MEDICINAL CHEMISTRY

IF6.8

2021-08-1719

OAAI

Targeted activity of the small molecule kinase inhibitor Pz-1 towards RET and TRK kinases

SCIENTIFIC REPORTS

IF3.9

2021-08-098

OAAI

AI-enabled remote monitoring of vital signs for COVID-19: methods, prospects and challenges

COMPUTING

IF2.8

2021-03-2953

PREAI

Pyrazoloadenine Inhibitors of the RET Lung Cancer Oncoprotein Discovered by a Fragment Optimization Approach

CHEMMEDCHEM

IF3.4

2021-03-083

A Review on the Role of Machine Learning in Enabling IoT Based Healthcare Applications

机器学习在实现基于物联网的医疗应用中的作用综述

IEEE ACCESS

IF3.6

2021-01-0174

OAAI

Pyrrolo[2,3-d]pyrimidine derivatives as inhibitors of RET: Design, synthesis and biological evaluation

吡咯并 [2，3-d] 嘧啶衍生物作为RET抑制剂的设计、合成及生物学评价

EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY

IF5.9

2020-11-0125

OAAI

Naga Rajiv Lakkaniga

个人简介

教育背景

工作经历

荣誉奖项

研究方向